S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
The Collapse of 2022 Has Begun (Ad)pixel
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
The Collapse of 2022 Has Begun (Ad)pixel
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
The Collapse of 2022 Has Begun (Ad)pixel
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
The Collapse of 2022 Has Begun (Ad)pixel
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving

FY2022 EPS Estimates for Gamida Cell Ltd. Lifted by Analyst (NASDAQ:GMDA)

Gamida Cell Ltd. (NASDAQ:GMDA - Get Rating) - Research analysts at HC Wainwright increased their FY2022 earnings per share (EPS) estimates for Gamida Cell in a report issued on Tuesday, November 15th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings of ($1.15) per share for the year, up from their prior forecast of ($1.24). The consensus estimate for Gamida Cell's current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Gamida Cell's Q4 2022 earnings at ($0.22) EPS, FY2023 earnings at ($0.74) EPS and FY2023 earnings at ($0.74) EPS.

Gamida Cell (NASDAQ:GMDA - Get Rating) last issued its earnings results on Monday, August 15th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). During the same period last year, the company earned ($0.42) earnings per share.

A number of other brokerages have also issued reports on GMDA. Piper Sandler reduced their price target on Gamida Cell from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Monday, October 3rd. Oppenheimer decreased their price target on Gamida Cell from $15.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Needham & Company LLC decreased their price target on Gamida Cell from $12.00 to $9.00 and set a "buy" rating for the company in a research note on Thursday, September 29th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $13.00.

Gamida Cell Stock Performance


Shares of NASDAQ GMDA opened at $1.85 on Thursday. Gamida Cell has a 12-month low of $1.47 and a 12-month high of $4.72. The company has a market cap of $109.52 million, a PE ratio of -1.45 and a beta of 1.63. The stock has a 50 day simple moving average of $1.90 and a 200-day simple moving average of $2.12. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 9.15.

Institutional Trading of Gamida Cell

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Gamida Cell during the second quarter valued at $36,000. Levin Capital Strategies L.P. purchased a new stake in shares of Gamida Cell during the third quarter valued at $40,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Gamida Cell during the second quarter valued at $42,000. OLD National Bancorp IN purchased a new stake in shares of Gamida Cell during the second quarter valued at $57,000. Finally, Stock Yards Bank & Trust Co. purchased a new stake in Gamida Cell in the 2nd quarter worth about $62,000. Institutional investors and hedge funds own 41.27% of the company's stock.

Gamida Cell Company Profile

(Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

See Also

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Gamida Cell right now?

Before you consider Gamida Cell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gamida Cell wasn't on the list.

While Gamida Cell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here